NCT04793620 is a Phase 1 clinical trial of TQL1055 in Pertussis, sponsored by Adjuvance Technologies, Inc..

Who is sponsoring NCT04793620?

NCT04793620 is sponsored by Adjuvance Technologies, Inc..

What drugs are being tested in NCT04793620?

Interventions in NCT04793620: TQL1055, Acellular pertussis vaccine.

Is NCT04793620 still recruiting?

NCT04793620 is currently terminated. Last updated 1 November 2022.

Last reviewed 2022-11-01 · How we verify

NCT04793620

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pertussis Acellular Vaccine Adjuvanted With TQL1055

Terminated Phase 1 Last updated 1 November 2022

What this trial tests

Phase 1 trial testing TQL1055 in Pertussis in 72 participants. Terminated before completion.

Timeline

6 April 2021

Primary endpoint
23 August 2021

14 February 2022

Quick facts

Lead sponsor	Adjuvance Technologies, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	prevention
Enrollment	72
Start date	6 April 2021
Primary completion	23 August 2021
Estimated completion	14 February 2022
Sites	1 location across Australia

Drugs / interventions tested

TQL1055
Acellular pertussis vaccine — full drug profile →

Conditions studied

Pertussis — all drugs for Pertussis →

Sponsor

Adjuvance Technologies, Inc. — full company profile →

Who can join

Adults 18 to 50, any sex, with Pertussis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1 study to evaluate the safety and immunogenicity of the semisynthetic saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Coping Strategies for Pertussis Resurgence.
Nian X, Liu H, Cai M, Duan K, et al · · 2023 · cited 19× · PMID 37242993 · DOI 10.3390/vaccines11050889
Correction: Nian et al. Coping Strategies for Pertussis Resurgence. <i>Vaccines</i> 2023, <i>11</i>, 889.
Nian X, Liu H, Cai M, Duan K, et al · · 2024 · PMID 38400201 · DOI 10.3390/vaccines12020151

Verify or expand the search:

Other recruiting trials for Pertussis

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT06708286 — A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) · Phase 2, PHASE3 · active not recruiting
NCT06184542 — Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine · Phase 1 · recruiting
NCT06286007 — Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control · recruiting
NCT06056050 — A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04793620 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adjuvance Technologies, Inc.
Last refreshed: 1 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04793620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing